ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0108

Efficacy of SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis

Akhil Sood1, Vijaya Murthy1 and Emilio Gonzalez2, 1University of Texas Medical Branch, League City, TX, 2University of Texas Medical Branch (utmb Health), Galveston, TX

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, COVID-19, Disease-Modifying Antirheumatic Drugs (Dmards), meta-analysis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The mRNA-based SARS-CoV-2 vaccine has shown efficacy in large vaccine trials. However, patients on immunosuppressive therapies including those with rheumatic disease (RD) were excluded. Recent studies have examined the immunogenicity of SARS-CoV-2 vaccination in immunocompromised patients. We thus conducted a systematic review and meta-analysis on the humoral immune response of SARS-CoV-2 vaccination in patients with rheumatic disease.

Methods: We systematically searched Pubmed/Medline, Scopus, and MedRxiv from January 1, 2021- May 30, 2021 to identify eligible studies that examined the immunogenicity of SARS-CoV-2 vaccination in RD patients. Included studies provided information on proportion of RD patients who developed an immune response following the second dose of the vaccine. Immune response was defined as development of IgG antibodies to SARS-CoV-2 S anti-receptor binding domain (RBD) or neutralizing antibodies with cutoffs established by manufacturer. Information on RD type and immunosuppressant use was also obtained from each study. Meta-Analysis was performed using Comprehensive Meta-Analysis.

Results: Our meta-analysis included eight studies (3 observational studies, 5 case-control studies) which was comprised of 1482 RD patients. The pooled response rate following vaccination against SARS-CoV-2 was 0.88 (95% CI 0.75-0.94). Compared to non-RD patients, RD patients had significantly decreased response to SARS-CoV-2 vaccination (RR 0.88, 95% 0.84-0.93). Patients on rituximab (37%), mycophenolate (70.8%), prednisone (86.6%), and methotrexate (91.9%) showed lower vaccine response. On the other hand, patients on TNF (100%), JAK (96.3%), and IL-17 inhibitors (92.9%) showed higher vaccine response.

Conclusion: In this systematic review and meta-analysis, majority of RD patients developed an immune response following second dose of SARS-CoV-2 vaccine. However, the vaccine response rate was significantly lower in RD patients compared to controls. This is likely driven by certain immunosuppressants particularly B-cell depleting therapy which can hamper the humoral immune response. Future studies need to examine the use and timing of these immunosuppressants prior to SARS-CoV-2 vaccination.


Disclosures: A. Sood, None; V. Murthy, None; E. Gonzalez, None.

To cite this abstract in AMA style:

Sood A, Murthy V, Gonzalez E. Efficacy of SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/efficacy-of-sars-cov-2-vaccine-in-patients-with-rheumatic-diseases-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-sars-cov-2-vaccine-in-patients-with-rheumatic-diseases-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology